Back to Report Store Home

Global Cancer Vaccines Market to 2022 – Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • Published: Nov-2016
  • Report Code: GBIHC424MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Symptoms 11

2.3 Etiology and Pathophysiology 12

2.3.1 Etiology 12

2.3.2 Cancer Pathophysiology 15

2.3.3 Virus Pathophysiology 16

2.4 Epidemiology Patterns – Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 16

2.4.1 Cervical Cancer 17

2.4.2 Liver Cancer 18

2.4.3 Melanoma 18

2.4.4 Prostate Cancer 19

2.5 Co-morbidities and Complications 20

2.6 Treatment 21

2.6.1 Surgery and Radiation Therapy 21

2.6.2 Chemotherapy 23

2.6.3 Hormonal Therapies 25

2.6.4 Targeted Therapies 26

2.6.5 Types of Cancer Vaccines 27

3 Key Marketed Products 31

3.1 Overview 31

3.2 Gardasil/Gardasil 9 31

3.3 Provenge 33

3.4 Cervarix 35

3.5 Imlygic 36

3.6 DCVax-L 37

3.7 Recombivax HB 39

3.8 Conclusion 39

4 Pipeline Landscape Assessment 41

4.1 Overview 41

4.2 Pipeline Development Landscape 41

4.2.1 Therapeutic Vaccine Molecule Type and Development Stage 41

4.2.2 Prophylactic Vaccine Molecule Type and Development Stage 42

4.2.3 Key Oncology Indications by Molecule Type and Development Stage 43

4.3 Pipeline by Molecular Targets and Indication 45

4.3.1 Therapeutic Vaccine Molecular Targets 45

4.4 Clinical Trials 48

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 48

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 52

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 56

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 59

4.4.5 Conclusion 63

4.5 Assessment of Key Pipeline Products 64

4.5.1 Tisagenlecleucel-T (CTL-019) – Novartis 64

4.5.2 KTE-C19 – Kite Pharma 65

4.5.3 JCAR017 – Juno Therapeutics 66

4.5.4 JCAR015 – Juno Therapeutics 67

4.5.5 bb-2121 – Bluebird Bio 68

4.5.6 Prostvac – Bavarian Nordic 69

4.5.7 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer – Kite Pharma 70

4.5.8 Conclusion 71

5 Multi-scenario Market Forecast to 2022 73

5.1 Overall Market Size 73

5.2 Prophylactic and Therapeutic Vaccine Market Split 75

5.3 Revenue Forecast by Molecular Target 78

5.3.1 HPV L1 Major Capsid Protein 78

5.3.2 Hepatitis B Surface Antigen 78

5.3.3 Cluster of Differentiation 19 79

5.3.4 Granulocyte Macrophage Colony Stimulating Factor 80

5.3.5 Tumor Necrosis Factor Receptor Superfamily Member 17 81

5.3.6 Prostatic Acid Phosphatase 82

6 Company Analysis and Positioning 83

6.1 Revenue and Market Share Analysis by Company 84

6.1.1 Merck & Co – How Will Cancer Vaccine Revenues Be Affected by Recombivax HB’s Patent Expiry? 88

6.1.2 GSK – How Will Its Prophylactic Vaccines Fair Against Merck & Co’s Competitors? 90

6.1.3 Novartis – How Will This Top 20 Company Perform in The Cancer Vaccines Market? 91

6.1.4 Kite Pharma – Could it Develop a Blockbuster? 92

6.1.5 Amgen – How Will Recent Approval Imlygic Perform? 93

6.1.6 Juno Therapeutics – Great Potential for its CD19 Targeting Therapies 93

6.1.7 Valeant Pharma – Uncertain Times and Financial Difficulties 94

6.1.8 Bluebird Bio – How Will This Small Company Perform in the Cancer Vaccines Market? 95

6.1.9 Bavarian Nordic – How Will Prostvac Perform? 95

6.2 Company Landscape 96

6.3 Marketed and Pipeline Portfolio Analysis 97

7 Strategic Consolidations 100

7.1 Licensing Deals 100

7.1.1 Deals by Region and Value 100

7.1.2 Deals by Indication, Stage of Development and Value 101

7.1.3 Deals by Molecule Type, Molecular Target and Value 103

7.1.4 Table for Licensing Deals with Disclosed Values 105

7.2 Co-development Deals 108

7.2.1 Deals by Region and Value 108

7.2.2 Deals by Indication, Stage of Development and Value 110

7.2.3 Deals by Molecule Type, Molecular Target and Value 111

7.2.4 Table for Co-development Deals With a Disclosed Value 113

8 Appendix 114

8.1 References 114

8.2 Table of All Pipeline Products 127

8.3 Abbreviations 182

8.4 Methodology 184

8.4.1 Coverage 184

8.4.2 Secondary Research 184

8.4.3 Market Size and Revenue Forecasts 184

8.4.4 Pipeline Analysis 185

8.4.5 Competitive Landscape 185

8.5 Contact Us 185

8.6 Disclaimer 186

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards